News

CEO Clive Dix spoke to Proactive Investors on today’s business update.

Talking about the collaboration with the GEN-COVID Consortium in Italy, Clive said "The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis."

Tuesday, 25 August 2020

Press Release Business Update

Continued progress across proprietary portfolio

Phase 1 clinical trial with C4X_3256 initiated by partner Indivior

New Taxonomy3® collaboration with the GEN-COVID Consortium, Italy, to examine COVID-19 genetics

25 August 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today provides a business update.

Head of Corporate Strategy and Development at C4XD, Bhavna Hunjan, spoke to Kevin Grogan at IN VIVO on business development and partnering strategies in drug discovery.

Bhavna Hunjan, Head of Corporate Strategy and Development at C4X Discovery talks about Business Development in a Virtual World.

Wednesday, 22 July 2020 - European Biopharmaceutical Review

In the News The Promise of Drug Discovery

C4XD's CSO, Craig Fox, speaks to European Biopharmaceutical Review on "The Promise of Drug Discovery".

Government’s taskforce to lead UK efforts to deliver a COVID-19 vaccine

5 June 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to confirm that Clive Dix, Chief Executive Officer of C4XD has been appointed a member and Deputy Chair of the Steering Board of the UK Vaccine Taskforce, the group set up by the Government’s Chief Scientific Adviser, Deputy Chief Medical Officer, Business Secretary and Health Secretary to lead UK efforts to find and manufacture a COVID-19 vaccine.

Successfully raises approximately £1.6 million led by Polar Capital

Advancing the next wave of out-licensing opportunities

7 May 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to announce the completion of the Placing announced earlier today.

Advancing the next wave of out-licensing opportunities

7 May 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces a proposed Placing of Placing Shares with existing and new institutional investors to raise a minimum of approximately £1.0 million in aggregate before expenses at the Issue Price of 15 pence per Placing Share.